BioSpace News Archive

Exactech, a developer and producer of innovative implants, instrumentation and smart technologies for joint replacement surgery, announced the launch of next-generation hardware and software for its ExactechGPS® guided personalized surgery system.

The investment will support the establishment of Ellume’s first U.S. manufacturing facility, increasing Ellume’s global production capacity by 500,000+ tests per day once completed

Decision to slash reimbursement rates limits patient and physician access to innovative ECG technologies proven to yield earlier detection and diagnosis of dangerous abnormal heart rhythms that disproportionately affect seniors

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, announced that on January 29, 2021, the Company granted stock options and restricted stock units to 92 new employees of the Company.

Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report its preliminary 2020 fourth quarter and full-year financial results and provide a corporate update on February 8, 2021

EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced that it intends to offer and sell shares of its common stock in an underwritten public offering.

Seer, Inc., a life sciences company commercializing a disruptive new platform for proteomics, today announced the closing of an underwritten public offering of 3,750,000 shares of Class A common stock at a public offering price of $67.00 per share, before deducting underwriting discounts and commissions

NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the appointment of Siddhartha Kadia, Ph.D. to the Company’s Board of Directors, effective February 1, 2021.

Intersect ENT, Inc., a global ear, nose and throat medical technology leader dedicated to transforming patient care, announced that Tom West, President & Chief Executive Officer, and Randy Meier, Executive Vice President & Chief Financial Officer, will participate in the following upcoming investor conferences:

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal first quarter ended December 31, 2020 after the U.S. markets close on February 8, 2021.